Lopera-Mesa Tatiana Maria, Kushwaha Ashima, Mohmmed Asif, Chauhan Virander Singh
International Centre for Genetic Engineering and Biotechnology, Aruna Asaf Ali Marg, PO Box 10504, New Delhi 110067, India.
Vaccine. 2008 Mar 4;26(10):1335-43. doi: 10.1016/j.vaccine.2007.12.042. Epub 2008 Jan 18.
Merozoite surface protein-9 (MSP-9) from Plasmodium is considered a promising vaccine candidate due to its location and possible role in erythrocyte invasion. We report the identification and characterization of Plasmodium berghei MSP-9 (PbMSP-9) and its properties as an immunogen using a recombinant PbMSP-9 fragment to immunize BALB/c mice. PbMSP-9 was found to harbor erythrocyte binding and serine protease activity. PbMSP-9 formulation in alum was highly immunogenic in BALB/c mice. To evaluate the protective efficacy, immunized mice were submitted to homologous challenge with P. berghei NK65 blood-stage parasites. Protection against the parasite challenge was observed in BALB/c mice immunized with the PbMSP-9 formulation. These results suggest for the first time that MSP-9 based immunogens may constitute part of an effective malaria vaccine.
由于疟原虫裂殖子表面蛋白9（MSP-9）的位置及其在红细胞入侵中可能发挥的作用，它被认为是一种很有前景的疫苗候选物。我们报告了伯氏疟原虫MSP-9（PbMSP-9）的鉴定与特性，以及使用重组PbMSP-9片段免疫BALB/c小鼠时其作为免疫原的特性。发现PbMSP-9具有红细胞结合和丝氨酸蛋白酶活性。明矾中的PbMSP-9制剂在BALB/c小鼠中具有高度免疫原性。为了评估保护效力，用伯氏疟原虫NK65血期寄生虫对免疫小鼠进行同源攻击。在用PbMSP-9制剂免疫的BALB/c小鼠中观察到了对寄生虫攻击的保护作用。这些结果首次表明基于MSP-9的免疫原可能构成有效疟疾疫苗的一部分。
